A new study finds a long-acting medication and a short-term drug that must be taken daily are equally effective in treating opioid addiction.
Researchers at NYU Langone Health found extended-release naltrexone (Vivitrol) was as safe and effective as more commonly prescribed buprenorphine-naloxone (Suboxone) in curtailing opioid use, relapse, treatment drop-out, and overdose.
The study, which was sponsored by the National Institute on Drug Abuse, was published in The Lancet.
The study is the first major head-to-head comparison of the treatments, according to The Washington Post. Researchers found each treatment had disadvantages. Short-acting medicines must be taken daily for years or even a lifetime. Naltrexone, which is given as a monthly injection, cannot be started until a person is fully detoxified from opioids—which more than 25 percent of the study subjects failed to do.
More than half of the study subjects relapsed at least once, regardless of which treatment they received.
- DEA Rule Allows Criminal Prosecution for Fentanyl Trafficking
- Teens Dependent on Marijuana and Alcohol Struggle with Success Later in Life
- Millions of Dollars Needed for Trump’s Anti-Opioid Ad Campaign, Advocates Say
- Combo of Acetaminophen and Ibuprofen as Effective as Opioids for Acute Pain
- Drug Overdose Deaths Rose More Than 17 Percent Last Year: CDC
- Hospitals Overwhelmed With Treating Diseases Resulting From IV Drug Use
- Teens Bring Juul E-Cigarette Device, Which Looks Like USB Flash Drive, to School
- NIAAA Alcohol Treatment Navigator: Pointing the Way to Quality Care
- DEA Collects Record Number Of Unused Pills As Part Of Its 14th Prescription Drug Take Back Day
- NIDA Launches Two Adolescent Substance Use Screening Tools
- Patients Treated with Naloxone Continue to be at High Risk of Overdose: Study
- New Rule Allows Health Providers to Share Information about Overdose with Family
- Addressing the Opioid Crisis Means Confronting Socioeconomic Disparities
- Drug Use Disorder vs. Drug Misuse - What is the Difference?
- NCADD Affiliate Executive Director Featured in NY Times Op Ed
- President’s Commission on Opioid Crisis Calls for Nationwide System of Drug Courts
- Fentanyl is Key Factor Driving Opioid Overdose Deaths: CDC
- Many Teens Who Take Adderall as “Study Drug” Unaware it is Amphetamine
- Giving Tuesday
- Drug Overdose Death Rates in Rural Areas Exceed Those in Cities